Hi-Tech Pharmacal Co., Inc. (HITK) F1Q2013 Earnings Conference Call Sep 5, 2012 10:00 AM ET Executives David Seltzer - President and Chief Executive Officer William Peters - Chief Financial Officer and Vice President of Finance Analysts Randall Stanicky - Canaccord Genuity Timothy Chiang - CRT Capital Group Sumant Kulkarni - Bank of America Merrill Lynch Scott Eisler - Moors & Cabot PresentationOperator
Good day, ladies and gentlemen, and welcome to the Quarter One and 2013 Hi-Tech Pharmacal Earnings Conference Call. My name is Lisa, and I'll be your operator for today. At this time, all participants are in a listen-only mode. We will conduct a question and answer session towards the end of the conference. [Operator Instructions] As a reminder, this call is being recorded for replay purposes. Before we begin the company has asked me to read the following statement. Forward-looking statements, statements which are not historical facts in this conference call, are made pursuant to the Safe Harbor provision of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are not promises or guarantees, and investors are cautioned that all forward-looking statements will involve risks and uncertainties including, but not limited to, the impact of competitive products and pricing; product demand and market acceptance; new product development; the regulatory environment, including, without limitation, reliance on key strategic alliances, availability of raw materials, fluctuations in operating results and other results; and other risks detailed from time to time in the company's filings with the Securities and Exchange Commission. These statements are based on management's current expectations and are naturally subject to uncertainty and changes in circumstances. We caution you not to place undue reliance upon any such forward-looking statements, which speak only as of the date made. Hi-Tech is under no obligation to and expressly disclaims any such obligation to update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.